News +
Events

We are happy to communicate effectively with all stakeholders by providing updates in the form of news and events on all aspects of our corporate and product development status.

News

First Patient Dosed in Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

Hangzhou, Suzhou China/New York, USA– June 17, 2021 – AnHeart Therapeutics Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global …

AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

Hangzhou, China June 7/New York June 6, 2021 – AnHeart Therapeutics Co., Ltd (“AnHeart”), a clinical stage oncology company focused on underserved patients in global …

AnHeart Therapeutics and Innovent Biologics Announce Exclusive License Agreement for Taletrectinib in Greater China

Hangzhou, Suzhou China/New York June 1st, 2021 – AnHeart Therapeutics Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, …

AnHeart Announces Upcoming Presentation of Preliminary Results from Phase II Trial of Taletrectinib in ROS1+ NSCLC at the ASCO 2021 Virtual Meeting

Hangzhou, China/New York May 19, 2021 – AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, announces …

AnHeart Announces Publication of Pooled Analysis of two Phase 1 Studies of Taletrectinib in ROS1+ NSCLC

Progression-Free Survival of 29.1 months reported in ROS1 TKI treatment-naïve patients and 14.1 months in patients pre-treated with one prior ROS1 TKI Hangzhou, China/New York …

AnHeart Licenses Two Clinical Stage Oncology Candidates from Daiichi Sankyo

Expanding Oncology Pipeline to Three Novel Molecules Following its Series A+ Financing Round   Hangzhou, China/New York – September 7, 2020 – AnHeart Therapeutics, Co., …

AnHeart Announces Entry into Series A+ Equity Financing Agreements

Proceeds to be Used for Advancing Taletrectinib Phase 2 Trials and Expanding Oncology Portfolio Hangzhou, China/New York – August 10, 2020 – AnHeart Therapeutics, Co., …

First Patient Dosed with Taletrectinib in AnHeart Phase 2 Trial of Non-Small Cell Lung Cancer with ROS1 Fusion

Shanghai, China/New York – July 21, 2020 – AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, …

AnHeart Therapeutics Announces License Agreement with NewG Lab for Taletrectinib Rights in Korea

Total of $7 million in milestone payments and royalty payments at double digit rates Hangzhou, China/New York, NY – July 15, 2020 – AnHeart Therapeutics, Co., …

AnHeart Therapeutics Announces Acceptance of Taletrectinib Phase 1 Data for Publication in Clinical Cancer Research

Hangzhou, China/New York, NY – June 26, 2020 – AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, …

Chinese Center for Drug Evaluation (CDE) Cleared Taletrectinib IND and Issued Clinical Trial Authorizations for Two Phase 2 Clinical Trials in China

HANGZHOU, China, March 23, 2020 (GLOBE NEWSWIRE) — AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, today …

Research results of AnHeart’s new-generation ROS1/NTRK inhibitor AB-106 published in Nature Communications

Research results of AnHeart’s new-generation ROS1/NTRK inhibitor AB-106 published in Nature Communications   HANGZHOU, Sept. 25 2019 /PRNewswire/ — The preclinical results of AB-106 (original …

AnHeart Therapeutics Won the 2019 Sullivan China New Economy

AnHeart Therapeutics Won the 2019 Sullivan China New Economy – Excellence in Innovation Award Frost & Sullivan, the world leading growth consulting company, awarded AnHeart …

AnHeart Therapeutics completed 100 million Chinese Yuan Series A round of financing; new anti-cancer drugs to enter China’s clinical trials

On May 15, 2019, AnHeart Therapeutics (Hangzhou) Co., Ltd.. (hereinafter referred to as AnHeart) announced the completion of the series A round of financing raising …

Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics

Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics   TOKYO and BASKING RIDGE, N.J. and NEW YORK, Dec. 17, 2018/PRNewswire/ — Daiichi Sankyo Company, …

Corporate Presentation

Get Updates

Events